Literature DB >> 18175165

Diagnostic performance of contrast-enhanced computed tomography in the immediate assessment of radiofrequency ablation success in colorectal liver metastases.

Christina Schraml1, Stephan Clasen, Nina F Schwenzer, Ingmar Koenigsrainer, Tina Herberts, Claus D Claussen, Philippe L Pereira.   

Abstract

BACKGROUND: To determine the accuracy of contrast-enhanced multislice computed tomography (CT) in the assessment of treatment success immediately after CT-guided radiofrequency (RF) ablation.
METHODS: 26 patients with 38 Colorectal liver metastasis (CRM) were treated by CT-guided RF ablation. Pre-contrast and portal phase CT features before and immediately after ablation were retrospectively evaluated quantitatively and qualitatively: Influence of attenuation characteristics, safety margin, congruency between tumor and coagulation, and morphological criteria (shape, margin distinction, margin configuration, and margin continuity) were investigated. Findings were statistically analyzed with regard to local tumor progression.
RESULTS: Mean observation period for follow-up scans was 6.4 months (range: 3-40 months). Attenuation characteristics, safety margin, and congruency had no significant effect on the probability of local tumor progression. Coagulations whose margin was categorized as "discontinuous" were significantly more often associated with local recurrence (p = 0.038). No significant influence on local recurrence could be detected regarding coagulation shape, margin distinction, and configuration.
CONCLUSION: Computed tomography imaging immediately after RF ablation allows for morphological characterization of the coagulation and provides a valid baseline status for follow-up imaging. However, in CRM, morphological image criteria and attenuation characteristics have limited predictive value for immediate detection of persistent tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175165     DOI: 10.1007/s00261-007-9351-9

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  13 in total

1.  Correlation between calcified liver metastases and histopathology of primary colorectal carcinoma in Chinese.

Authors:  Liying Xu; Yunfeng Zhou; Dasheng Qiu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

2.  Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases.

Authors:  Xiaodong Wang; Constantinos T Sofocleous; Joseph P Erinjeri; Elena N Petre; Mithat Gonen; Kinh G Do; Karen T Brown; Anne M Covey; Lynn A Brody; William Alago; Raymond H Thornton; Nancy E Kemeny; Stephen B Solomon
Journal:  Cardiovasc Intervent Radiol       Date:  2012-04-26       Impact factor: 2.740

3.  Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation.

Authors:  Wei Teng; Ka-Wai Liu; Chen-Chun Lin; Wen-Juei Jeng; Wei-Ting Chen; I-Shyan Sheen; Chun-Yen Lin; Shi-Ming Lin
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

4.  Intra-operative ultrasound elasticity imaging for monitoring of hepatic tumour thermal ablation.

Authors:  Mark G Van Vledder; Emad M Boctor; Lia R Assumpcao; Hassan Rivaz; Pezhman Foroughi; Gregory D Hager; Ulrike M Hamper; Timothy M Pawlik; Michael A Choti
Journal:  HPB (Oxford)       Date:  2010-12       Impact factor: 3.647

5.  Radiofrequency Ablation of Hepatic Tumor: Subjective Assessment of the Perilesional Vascular Network on Contrast-Enhanced Computed Tomography Before and After Ablation Can Reliably Predict the Risk of Local Recurrence.

Authors:  Sireesha Yedururi; Silanath Terpenning; Sanjay Gupta; Patricia Fox; Sooyoung Shin Martin; Claudius Conrad; Evelyne M Loyer
Journal:  J Comput Assist Tomogr       Date:  2017 Jul/Aug       Impact factor: 1.826

6.  Periodic contrast-enhanced computed tomography for thermal ablation monitoring: a feasibility study.

Authors:  Christopher L Brace; Charles A Mistretta; J Louis Hinshaw; Fred T Lee
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009

7.  Contrast enhanced ultrasound: Roles in immediate post-procedural and 24-h evaluation of the effectiveness of thermal ablation of liver tumors.

Authors:  M F Meloni; A Andreano; F Zimbaro; M Lava; S Lazzaroni; S Sironi
Journal:  J Ultrasound       Date:  2012-09-29

8.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

9.  Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma.

Authors:  Robert Peter Reimer; Nils Große Hokamp; Julius Niehoff; David Zopfs; Simon Lennartz; Mariam Heidar; Roger Wahba; Dirk Stippel; David Maintz; Daniel Pinto Dos Santos; Christian Wybranski
Journal:  PLoS One       Date:  2021-06-15       Impact factor: 3.240

10.  Clinical outcome, proteome kinetics and angiogenic factors in serum after thermoablation of colorectal liver metastases.

Authors:  Marieke W J L A E Wertenbroek; Marianne Schepers; Hannetta J Kamminga-Rasker; Jan T Bottema; Anneke C Muller Kobold; Han Roelofsen; Koert P de Jong
Journal:  BMC Cancer       Date:  2013-05-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.